The European Society for Medical Oncology (ESMO) Conference on Gynecological Cancers in Europe will serve as a hub of information demonstrated by healthcare professionals focused on the care of women with gynecological cancer. This year’s conference, to be held June 20 to June 22, 2024, in Florence, Italy (with a virtual option), offers a dynamic and interactive learning experience.
Sessions will include presentations, discussions, and networking opportunities to empower participants to provide top-quality care to patients, and the ESMO Gynecological Cancers Scientific Co-Chairs will lead the conference:
- Susana Banerjee (ICR London, UK)
- Domenica Lorusso (Catholic University of Rome Milan, Italy)
- Bradley J. Monk (Florida Cancer Specialists & Research Institute, West Palm Beach, FL, USA)
- Ana Oaknin (IOB, Barcelona, Spain)
ESMO-GC 2024 To Explore Gynecological Malignancies In Depth
The ESMO-GC 2024 will provide a deep understanding of the prognosis, biology, and therapy of gynecological malignancies. It will comprise educational and scientific programs, including sessions to provide participants with the most recent information and best practices. The sessions will include:
-
- Progress in the practice of the management of gynecologic cancers: Participants will exchange ideas on the new treatment approaches as well as on recent advancements that radically change patient outcomes.
- Progresses in PARP inhibitors for ovarian cancers: This session details the latest research on PARP inhibitors, a promising drug therapy for ovarian carcinomas.
- The latest development in diagnosis and treatment of endometrial and cervical cancer: A perspective on the new techniques for diagnosing and treating common gynecological malignancies.
- The evolving role of surgical operations and HIPEC in gynecological cancers: This session will discuss the role of surgery, including HIPEC.
- Novel therapeutic approaches for rare gynecological cancer: The conference focuses on novel therapeutic approaches to rare gynecological malignancies, including the modern strategies discussed for managing rarely occurring gynecological cancers.
- Progress in the practice of the management of gynecologic cancers: Participants will exchange ideas on the new treatment approaches as well as on recent advancements that radically change patient outcomes.
Role Of Precision Medicine To Be Explored at ESMO-GC 2024
Precision Medicine will be one of the key areas of focus at the ESMO-GC 2024. The conference will present established and novel biomarkers employed in the personalized treatment of patients with gynecological cancers. Sessions will discuss progress in the following areas:
- Profiling and risk stratification: Tumor profiling based on personalized treatment to improve treatment decisions and predict patient outcomes.
- Novel therapies: Gain perspective on recently developed targeted therapies and immunotherapies that are specific to cancer subtypes.
Learning Opportunities Throughout ESMO-GC 2024
Through participation in ESMO-GC 2024, attendees will have the opportunity to:
- Gain deeper insights into gynecological cancer management from the best experts;
- Stay updated with the recent progress of diagnostic methods, risk stratification, and treatments to guarantee the best patient care;
- Expand their knowledge of well-established and recently discovered biomarkers for personalized medicine and therapy selection in gynecological cancers.
ESMO Colloquium at ESMO-GC 2024
In addition to the main program, the ESMO Gynecological Cancers Conference 2024 will feature an ESMO Colloquium dedicated to exploring the latest advancements in ovarian cancer treatment.
The session, led by Nicoletta Colombo (IGCS from Milan, Italy) and Frederik Marmé (University Hospital Mannheim from Mannheim, Germany), will take a deep dive into key areas, including:
- Biological insights: It will help participants better understand the biological pathways involved in the development of ovarian cancer and the resistance mechanisms to platinum-based therapies.
- Advanced treatment options: This session will help participants learn the state-of-the-art management strategies for patients with platinum-resistant ovarian cancer.
- Promising Antibody Drug Conjugates (ADCs): This section will explore the emerging field of ADC therapy, including its mechanism of action and promising novel drugs being developed for ovarian cancer.
Condition Spotlight: Deep Dive into Specific Cancers
Beyond the main program, the ESMO Gynecological Cancers Conference 2024 will offer focused sessions on specific gynecological cancers, providing in-depth explorations of key areas:
- Advances in Endometrial and Cervical Cancer: Enhancing Treatment Strategies and Guideline-Concordant Care (Thursday, 13:30 – 14:30):
It will delve into the latest advancements in treatment strategies for endometrial and cervical cancers. It will emphasize the importance of following established guidelines to ensure optimal patient care. Speakers will be Shannon Westin (MD Anderson Cancer Center Houston,Texas, USA) Sandro Pignata (IRCCS National Cancer Institute “Fondazione G. Pascale”, Italy) and Toon Van Gorp (University Hospital Leuven, Belgium). Sponsored by MSD.
- Empowering Progress: Enhancing Long-Term Prognosis for Patients with Newly-Diagnosed Advanced Ovarian Cancer (Thursday, 18:30 – 19:30):
It will focus on improving the long-term prognosis for patients who have recently been diagnosed with advanced ovarian cancer. Speakers will be Vanda Salutari (Gemelli University Hospital, Rome, Italy), Nicoletta Colombo (University of Milan-Bicocca, Milan, Italy), and Antonio González-Martín (Clínica Universidad de Navarra, Madrid, Spain) Sponsored by MSD.
- Paradigm Shifts and Improving Outcomes for Patients with dMMR/MSI-H Endometrial Cancer (Friday, 13:15 – 14:15):
This session will highlight the significant changes in the treatment of endometrial cancer for patients with a specific genetic profile: mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H). Speakers will be Dr Sandro Pignata (Istituto Nazionale dei Tumori IRCCS Fondazione Pascale, Naples, Italy), Prof Christian Marth (Medical University of Innsbruck, Austria), and Ms Andreia Fernandes (The Royal Marsden NHS Foundation Trust, London, UK). Sponsored by GSK.
Research Highlights
- Patient-Reported Outcomes: The conference will have presentations on patient-reported outcomes (PROs) in various gynecological cancer treatments. PROs measure how patients feel and function with their disease and treatment, providing valuable insights beyond traditional clinical measures.
- Advancements in Cervical Cancer Care: The conference will highlight the novel treatment options for cervical cancer.
- Coformulated vibostolimab/pembrolizumab in advanced cervical cancer: KEYVIBE-005.
Presenter: Alexandra Leary, Institut de Cancérologie Gustave Roussy (France). - Exploring the prognostic value of circulating tumor HPV DNA in cervical cancer.
Presenter: Hao Wen, Fudan University (Shanghai, China).
- Coformulated vibostolimab/pembrolizumab in advanced cervical cancer: KEYVIBE-005.
Future Prospects
The ESMO-GC 2024 will pave the way for future advancements in the treatment of gynecological cancer. By fostering collaboration amongst global specialists and disseminating the current scientific findings, the conference will assist in shaping the subsequent era of diagnostic and therapeutic processes.
Attendees will gain insight into novel therapeutic techniques that can be implemented in a practical field, ultimately enhancing patient care. The attention to personalized medicines, innovative therapies, and comprehensive care ensures that the future of gynecological oncology holds promise for greater effective treatments and progressed outcomes for patients globally.
Event Sponsors
Platinum Sponsors: AstraZeneca, GSK, ImmunoGen, and MSD.
Silver Sponsors: Eisai EMEA, Menarini Stemline, and Mural Oncology.
Bronze Sponsors: Daiichi Sankyo.
